Literature DB >> 1932896

More macrolides.

M J Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1932896      PMCID： PMC1671102          DOI： 10.1136/bmj.303.6803.594

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  17 in total

1.  Chemotherapy for infections caused by Haemophilus influenzae: current problems and future prospects.

Authors:  M Powell
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

2.  Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.

Authors:  P B Fernandes; N Ramer; R A Rode; L Freiberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

3.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

Authors:  T Pullar; A J Birtwell; P G Wiles; A Hay; M P Feely
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

5.  Antibacterial activity of roxithromycin: a laboratory evaluation.

Authors:  J F Chantot; A Bryskier; J C Gasc
Journal:  J Antibiot (Tokyo)       Date:  1986-05       Impact factor: 2.649

6.  In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.

Authors:  B Olsson-Liljequist; B M Hoffman
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

7.  The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis.

Authors:  P Karma; J Pukander; M Penttilä; J Ylikoski; S Savolainen; L Olén; I Melén; S Löth
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

8.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 9.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-04       Impact factor: 7.616

10.  A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.

Authors:  J T Grayston; C C Kuo; S P Wang; J Altman
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245
View more
  5 in total

1.  In vivo administration of azithromycin affects lymphocyte activity in vitro.

Authors:  J Tomazic; V Kotnik; B Wraber
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

2.  Why use erythromycin?

Authors:  R J White
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

3.  Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.

Authors:  J T MacFarlane; J Prewitt; P Gard; A Guion
Journal:  Br J Gen Pract       Date:  1996-06       Impact factor: 5.386

4.  Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis.

Authors:  D Adam
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

5.  Repeat consultations after antibiotic prescribing for respiratory infection: a study in one general practice.

Authors:  P Davey; D Rutherford; B Graham; B Lynch; M Malek
Journal:  Br J Gen Pract       Date:  1994-11       Impact factor: 5.386
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.